真菌感染症診断市場：タイプ、診断方法、エンドユーザー別-2025～2030年の世界予測

真菌感染症診断市場は、2023年に20億9,000万米ドルと評価され、2024年には22億3,000万米ドルに達すると予測され、CAGR 6.96％で成長し、2030年には33億5,000万米ドルに達すると予測されています。

真菌感染症診断市場の範囲には、医療現場における真菌病原体の特定を目的とした、分子診断法、免疫診断法、その他の伝統的技術を含む診断法が含まれます。その必要性は、免疫不全患者の増加や病原体の拡散に影響を及ぼす気候変動などの要因に起因する、様々な集団における真菌感染症の発生率の上昇から生じています。最終用途は病院、クリニック、ラボに及び、医療プロバイダー、研究者、製薬会社などが含まれます。主要成長要因としては、診断技術の進歩、認知度の向上、感染症管理に対する政府の資金援助などが挙げられます。迅速で非侵襲的な診断ツールの開発と、予測診断のためのAIと機械学習の統合に潜在的なビジネス機会があります。企業はPOCT（ポイントオブケア検査）機能の拡充に注力すべきです。POCTは迅速な診断が可能であり、資源不足の地域では特に有益です。課題としては、先進的診断システムの高コスト、発展途上地域における医療への限られたアクセス、他の疾患と症状が重複することによる真菌病原体の同定の複雑さなどが挙げられます。携帯可能な診断技術、早期発見のための新規バイオマーカー、人件費を削減しながら精度を高めることができる自動化システムなどの技術革新が可能です。真菌の耐性メカニズムの解明や既存の診断ツールの感度向上に関する調査は、市場の高度化をさらに促進する可能性があります。現在、市場はダイナミックな動きを見せており、バイオテクノロジー企業からの関心が高まっているほか、スマート診断薬の開発に向けて医療機関とハイテク企業との提携も増加しています。企業がこの市場をナビゲートする際には、医療教育に戦略的に焦点を当て、診断へのアクセシビリティを高めるために政府機関や非政府組織と提携することが有益となる可能性があります。手頃な価格への対応や新しい診断ソリューションの承認プロセスの迅速化は、制限を緩和し成長を加速させる可能性があります。

市場力学：急速に進化する真菌感染症診断市場の主要市場洞察を公開

真菌感染症診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 真菌感染症の流行と効果的な診断方法の必要性
  • 真菌感染症管理に対する認識を促進する政府の取り組み
  • 真菌感染症検査シリーズに対する好意的な承認
• 市場抑制要因
  • 分子と遺伝子による真菌感染症診断の複雑さ
• 市場機会
  • 分子とポイントオブケア診断技術の進歩
  • 真菌感染症検出・診断における遠隔皮膚科学の可能性
• 市場課題
  • 診断法の不正確さに伴う限界

ポーターのファイブフォース：真菌感染症診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：真菌感染症診断市場における外部からの影響の把握

外部マクロ環境要因は、真菌感染症診断市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：真菌感染症診断市場における競合情勢の把握

真菌感染症診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：真菌感染症診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、真菌感染症診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：真菌感染症診断市場における成功への道筋を描く

真菌感染症診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 真菌感染症の蔓延と効果的な診断方法の必要性
    • 真菌感染症管理の意識を高める政府の取り組み
    • 真菌感染症検査シリーズが承認
  • 抑制要因
    • 分子遺伝学的真菌感染症診断の複雑さ
  • 機会
    • 分子診断技術とポイントオブケア診断技術の進歩
    • 真菌感染症の検出と診断における遠隔皮膚科の可能性
  • 課題
    • 診断方法の不正確さに関連する限界
• 市場セグメンテーション分析
  • タイプ：患者の免疫力の低下による日和見真菌感染症の発生率の増加
  • 診断方法：細胞生物学と分子生物学の進歩により、感染検出のための分子診断法が採用されるようになった
  • エンドユーザー：医療費の増大により、真菌感染症の診断を行う病院の重要性が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 真菌感染症診断市場：タイプ別

• イントロダクション
• 風土病性真菌感染症
• 日和見真菌感染症
• 皮下真菌感染症
• 表面真菌感染症
• 全身性真菌感染症

第7章 真菌感染症診断市場：診断方法別

• イントロダクション
• 抗原検査
• 皮膚科検査
• 組織病理学
• 微生物培養
• 分子診断
• 血清学

第8章 真菌感染症診断市場：エンドユーザー別

• イントロダクション
• 病院
• ポイントオブケア
• 研究機関
• 専門クリニック

第9章 南北アメリカの真菌感染症診断市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の真菌感染症診断市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの真菌感染症診断市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ミネソタ大学の研究チームが真菌性髄膜炎に対する新たな抗真菌療法の検査に成功
  • Applied BioCode、研究用真菌パネルアッセイの発売を発表
  • アリゾナ大学の研究者がアリゾナ州の廃水中の致命的な菌類の追跡に協力
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alexion Pharmaceuticals, Inc.
• Amgen Inc.
• Associates of Cape COD, Inc. by Seikagaku Group company
• Astellas Pharma Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• BioMerieux SA
• Bruker Corporation
• Danaher Corporation
• Eli Lilly and Company
• ELITech Group
• Eurofins Viracor, LLC
• F. Hoffmann-La Roche AG
• Hologic, Inc.
• Immununexpress Inc.
• IMMY
• InBios International, Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Norgen BIoTek Corp.
• PerkinElmer, Inc.
• Polysciences, Inc.
• Qiagen N.V.
• Siemens Healthineers
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET RESEARCH PROCESS
• FIGURE 2. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET DYNAMICS
• TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOLOGICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 37. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 54. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 57. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 109. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 121. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 124. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 153. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

The Fungal Infections Diagnosis Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.23 billion in 2024, and is projected to grow at a CAGR of 6.96%, to USD 3.35 billion by 2030.

The scope of the fungal infections diagnosis market encompasses diagnostic methods, including molecular diagnostics, immunodiagnostics, and other traditional techniques, aimed at identifying fungal pathogens in medical settings. The necessity arises from the rising incidence of fungal infections across various populations, attributed to factors like increasing immunocompromised patients and climate change affecting pathogen spread. Application extends to hospitals, clinics, and laboratories, with end-use scope involving healthcare providers, researchers, and pharmaceutical companies. Key growth influencers include advancements in diagnostic technologies, increasing awareness, and government funding for infectious disease management. Potential opportunities lie in the development of rapid, non-invasive diagnostic tools and the integration of AI and machine learning for predictive diagnostics. Companies should focus on expanding POCT (point-of-care testing) capabilities, which can provide quicker diagnoses and are particularly beneficial in under-resourced regions. Challenges include high costs of advanced diagnostic systems, limited access to healthcare in developing regions, and the complexity of fungal pathogen identification due to overlapping symptoms with other diseases. Innovations can be directed towards portable diagnostic technologies, novel biomarkers for early detection, and automated systems that can enhance accuracy while reducing labor costs. Research on understanding the resistance mechanisms of fungal strains and improving the sensitivity of existing diagnostic tools could further drive market sophistication. The market is currently dynamic, with a growing interest from biotech firms and increasing collaborations between healthcare organizations and tech companies to develop smart diagnostics. As businesses navigate this market, a strategic focus on healthcare education and partnerships with governmental and non-governmental organizations to enhance diagnostic accessibility could be beneficial. Addressing affordability and speeding up approval processes for new diagnostic solutions could mitigate limitations and accelerate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fungal Infections Diagnosis Market

The Fungal Infections Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of fungal infections and need for effective diagnosis methods
  • Government initiatives promoting awareness of fungal infection management
  • Favorable approvals for fungal infection test series
• Market Restraints
  • Complexity of molecular and genetic fungal infection diagnosis
• Market Opportunities
  • Advancements in molecular and point-of-care diagnosis technologies
  • Potential of teledermatology in fungal infection detection and diagnosis
• Market Challenges
  • Limitations associated with the inaccuracy of the diagnostic methods

Porter's Five Forces: A Strategic Tool for Navigating the Fungal Infections Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fungal Infections Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fungal Infections Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fungal Infections Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fungal Infections Diagnosis Market

A detailed market share analysis in the Fungal Infections Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fungal Infections Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fungal Infections Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fungal Infections Diagnosis Market

A strategic analysis of the Fungal Infections Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Endemic Fungal Infections, Opportunistic Fungal Infections, Subcutaneous Fungal Infections, Superficial Fungal Infections, and Systemic Fungal Infections.
• Based on Diagnostic Method, market is studied across Antigen Testing, Dermatological Examination, Histopathology, Microbiological Culture, Molecular Diagnostics, and Serology.
• Based on End-User, market is studied across Hospitals, Point-of-Care Settings, Research Institutions, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
    • 5.1.1.2. Government initiatives promoting awareness of fungal infection management
    • 5.1.1.3. Favorable approvals for fungal infection test series
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
    • 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
  • 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
  • 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Fungal Infections Diagnosis Market, by Type

• 6.1. Introduction
• 6.2. Endemic Fungal Infections
• 6.3. Opportunistic Fungal Infections
• 6.4. Subcutaneous Fungal Infections
• 6.5. Superficial Fungal Infections
• 6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

• 7.1. Introduction
• 7.2. Antigen Testing
• 7.3. Dermatological Examination
• 7.4. Histopathology
• 7.5. Microbiological Culture
• 7.6. Molecular Diagnostics
• 7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Point-of-Care Settings
• 8.4. Research Institutions
• 8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
  • 12.3.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
  • 12.3.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alexion Pharmaceuticals, Inc.
• 3. Amgen Inc.
• 4. Associates of Cape COD, Inc. by Seikagaku Group company
• 5. Astellas Pharma Inc.
• 6. Becton, Dickinson and Company
• 7. Bio-Rad Laboratories, Inc.
• 8. BioMerieux SA
• 9. Bruker Corporation
• 10. Danaher Corporation
• 11. Eli Lilly and Company
• 12. ELITech Group
• 13. Eurofins Viracor, LLC
• 14. F. Hoffmann-La Roche AG
• 15. Hologic, Inc.
• 16. Immununexpress Inc.
• 17. IMMY
• 18. InBios International, Inc.
• 19. Laboratory Corporation of America Holdings
• 20. Merck KGaA
• 21. Norgen Biotek Corp.
• 22. PerkinElmer, Inc.
• 23. Polysciences, Inc.
• 24. Qiagen N.V.
• 25. Siemens Healthineers
• 26. Takeda Pharmaceutical Company Limited
• 27. Thermo Fisher Scientific Inc.